Novo Nordisk Suffers Loss Against Biden Drug Price Plan (2)

Novo Nordisk’s attempt to block a government drug price-setting program was denied by a federal judge Wednesday, handing another win to the Biden administration as it continues to implement its plan aimed at curbing Medicare drug costs.

Judge Zahid N. Quraishi of the US District Court for the District of New Jersey rejected a gamut of arguments from Novo Nordisk A/S that alleged the Medicare Drug Price Negotiation Program compels speech, violates separation of powers, and is involuntary.

The program was created by the Inflation Reduction Act to slash the costs of Medicare Part D prescription drugs the government spends ...